EUVIMEDEUVIMED entdecken
Crossref

Subconjunctival injectable platelet-rich fibrin for severe dry eye disease: Preliminary clinical results

Huri Sabur, Ayse Nur Coban, Nese Arslan, Alperen Bahar

Graefe's Archive for Clinical and Experimental Ophthalmology · 2026

DOI: 10.1007/s00417-026-07256-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2026. Verfasst von Huri Sabur und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Bolu Izzet Baysal State Hospital, Bolu, Turkey. drhurisabur@gmail.com. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Conjunctiva, Platelet-Rich Fibrin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the prelaminary clinical effects of subconjunctival injectable platelet-rich fibrin (i-PRF) in patients with severe dry eye disease (DED). METHODS: This study included two groups: an i-PRF group consisting of 28 eyes treated with subconjunctival i-PRF injection and a control group of 32 eyes. The ocular surface disease index (OSDI-12), tear break-up time (TBUT), corneal fluorescein staining (CFS), tear meniscus height (TMH), and tear meniscus area (TMA) were assessed at baseline and during follow-up. Changes in clinical parameters were compared between the groups. RESULTS: Baseline demographic characteristics and dry eye parameters were comparable between the groups (all p > 0.05). After three injections, the i-PRF group showed a significantly greater reduction in OSDI-12 and CFS scores, as well as a significant increase in TBUT, compared with the control group. Tear meniscus parameters also improved in the i-PRF group, with TMH increasing from 145.9 ± 28.5 (143.0) to 254.3 ± 35.3 (258.5) µm and TMA from 0.015 ± 0.004 (0.016) to 0.043 ± 0.005(0.043) mm². CONCLUSION: Subconjunctival i-PRF injection was associated with improvements in both subjective symptoms and objective ocular surface parameters in patients with severe DED. These preliminary results suggest that i-PRF may be a promising adjunctive treatment option for patients refractory to conventional therapies. Further prospective controlled studies with longer follow-up are needed to confirm its efficacy and durability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dry Eye SyndromesConjunctivaPlatelet-Rich FibrinHumansFemaleMaleFollow-Up StudiesTearsMiddle AgedTreatment OutcomeInjections, IntraocularAdultProspective StudiesSeverity of Illness Index

Stichwörter der Autor:innen

Dry eye diseaseInjectable platelet-rich fibrinOSDITBUTTMATMH

Autor:innen und Institutionen

  • Department of Ophthalmology, Bolu Izzet Baysal State Hospital, Bolu, Turkey. drhurisabur@gmail.com.
  • Department of Ophthalmology, Hakkari State Hospital, Hakkari, Turkey.
  • Department of Ophthalmology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.

Zitieren

APA

Sabur, H., Coban, A. N., Arslan, N., & Bahar, A. (2026). Subconjunctival injectable platelet-rich fibrin for severe dry eye disease: Preliminary clinical results. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-026-07256-7

Vancouver

Sabur H, Coban AN, Arslan N, Bahar A. Subconjunctival injectable platelet-rich fibrin for severe dry eye disease: Preliminary clinical results. Graefe's Archive for Clinical and Experimental Ophthalmology. 2026. doi:10.1007/s00417-026-07256-7

BibTeX
@article{Sabur2026,
  author = {Sabur, Huri and Coban, Ayse Nur and Arslan, Nese and Bahar, Alperen},
  title = {Subconjunctival injectable platelet-rich fibrin for severe dry eye disease: Preliminary clinical results},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2026},
  doi = {10.1007/s00417-026-07256-7}
}
Kostenlos starten →